Table 2. Prophylaxis for EBV-induced... | Rockefeller University Press

Table 2.

Prophylaxis for EBV-induced PTLD (or treatment for increased EBV DNA levels)

EBV-specific T cell activator	T cell source	Prophylaxis for	EBV-specific pathology	References
LCL	Transplant donor derived	Post-HSCT PTLD	0/101 developed PTLD	Rooney et al., 1995, 1998; Heslop et al., 1996, 2010
			5/6 exhibited a decrease in EBV DNA	Gustafsson et al., 2000
			1/4 decrease in EBV DNA	Comoli et al., 2007
	Allogeneic	Post-HSCT PTLD	0/1 showed evidence of viral activation (EBV, CMV, ADV)	Naik et al., 2016
DCs + LCLs transduced with ADV	Transplant donor derived	Post-HSCT PTLD	0/1 showed evidence of viral activation (EBV, CMV, ADV)
DCs + LCLs transduced with ADV + CMV pp65	Transplant donor derived	Post-HSCT PTLD	0/2 showed evidence of viral activation (EBV, CMV, ADV)
	Allogeneic	Post-HSCT PTLD	0/3 showed evidence of viral activation (EBV, CMV, ADV)
Viral Ags from EBV, CMV, ADV	Transplant donor derived	Post-HSCT PTLD	0/2 showed evidence of viral activation (EBV, CMV, ADV)

EBV-specific T cell activator	T cell source	Prophylaxis for	EBV-specific pathology	References
LCL	Transplant donor derived	Post-HSCT PTLD	0/101 developed PTLD	Rooney et al., 1995, 1998; Heslop et al., 1996, 2010
			5/6 exhibited a decrease in EBV DNA	Gustafsson et al., 2000
			1/4 decrease in EBV DNA	Comoli et al., 2007
	Allogeneic	Post-HSCT PTLD	0/1 showed evidence of viral activation (EBV, CMV, ADV)	Naik et al., 2016
DCs + LCLs transduced with ADV	Transplant donor derived	Post-HSCT PTLD	0/1 showed evidence of viral activation (EBV, CMV, ADV)
DCs + LCLs transduced with ADV + CMV pp65	Transplant donor derived	Post-HSCT PTLD	0/2 showed evidence of viral activation (EBV, CMV, ADV)
	Allogeneic	Post-HSCT PTLD	0/3 showed evidence of viral activation (EBV, CMV, ADV)
Viral Ags from EBV, CMV, ADV	Transplant donor derived	Post-HSCT PTLD	0/2 showed evidence of viral activation (EBV, CMV, ADV)

Abbreviations used: ADV, adenovirus.